Tyra Biosciences, Inc. (TYRA) stock
TYRANasdaqPharmaceutical PreparationsFiscal year ends December 31
$19.57−0.17 (-0.86%)
Close on Nov 17, 2026Market cap $1.17BP/E –Yield –
Tyra Biosciences cash
Cash and short-term investments held at the end of each period.
Tyra Biosciences's cash was $73.84M at Jun 30, 2026. For fiscal 2025 it was $77.39M, down 16.8% from the year before. The highest annual figure on record is $302.43M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $77.39M | -16.8% |
| FY2024 | Dec 31, 2024 | $92.97M | +57.6% |
| FY2023 | Dec 31, 2023 | $59.01M | -76.6% |
| FY2022 | Dec 31, 2022 | $252.21M | -16.6% |
| FY2021 | Dec 31, 2021 | $302.43M | +1855.3% |
| FY2020 | Dec 31, 2020 | $15.47M | +14221.3% |
| FY2019 | Dec 31, 2019 | $108.00K | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $73.84M | -25.0% |
| Q1 FY2026 | Mar 31, 2026 | $84.96M | -15.7% |
| Q4 FY2025 | Dec 31, 2025 | $77.39M | -16.8% |
| Q3 FY2025 | Sep 30, 2025 | $61.95M | -40.4% |
| Q2 FY2025 | Jun 30, 2025 | $98.49M | -1.0% |
| Q1 FY2025 | Mar 31, 2025 | $100.72M | -60.4% |
| Q4 FY2024 | Dec 31, 2024 | $92.97M | +57.6% |
| Q3 FY2024 | Sep 30, 2024 | $103.89M | -51.8% |
| Q2 FY2024 | Jun 30, 2024 | $99.49M | -57.2% |
| Q1 FY2024 | Mar 31, 2024 | $254.37M | +5.2% |
| Q4 FY2023 | Dec 31, 2023 | $59.01M | -76.6% |
| Q3 FY2023 | Sep 30, 2023 | $215.65M | -18.1% |
| Q2 FY2023 | Jun 30, 2023 | $232.41M | -15.5% |
| Q1 FY2023 | Mar 31, 2023 | $241.70M | -17.4% |
| Q4 FY2022 | Dec 31, 2022 | $252.21M | -16.6% |
| Q3 FY2022 | Sep 30, 2022 | $263.21M | -15.9% |
| Q2 FY2022 | Jun 30, 2022 | $275.11M | +103.5% |
| Q1 FY2022 | Mar 31, 2022 | $292.50M | +108.0% |
| Q4 FY2021 | Dec 31, 2021 | $302.43M | +1855.3% |
| Q3 FY2021 | Sep 30, 2021 | $312.82M | +1631.4% |
| Q2 FY2021 | Jun 30, 2021 | $135.20M | +125088.9% |
| Q1 FY2021 | Mar 31, 2021 | $140.64M | – |
| Q4 FY2020 | Dec 31, 2020 | $15.47M | – |
| Q3 FY2020 | Sep 30, 2020 | $18.07M | – |
| Q4 FY2019 | Dec 31, 2019 | $108.00K | – |
See a number that looks wrong?